We studied a patient who had a typical seronegative rheumatoid arthritis (RA) and an immunodeficiency with hyper-IgM (HIM syndrome). CD40L was normally expressed by activated T cells, but CD40-mediated signal transduction was defective in B cells, preventing heavy chain switching (CD40L+ type of the HIM syndrome). These data suggest that a typical RA can develop in at least some patients with dysfunction of the CD40 pathway, i.e. in the absence of a normal co-operation between T and B cells. Accordingly, the blockade of CD40L-CD40 interactions, which has been proposed as a treatment of RA, might not be adapted to all patients. Interference with CD40L-CD40 interactions has been advocated as a potential immunosuppressive strategy that can be applied to the treatment of immune diseases [4] . Because the administration of an antibody to CD40L inhibits the onset of collagen type II-induced arthritis in susceptible strains of mice, blockade of the CD40 pathway has been proposed in the treatment of human rheumatoid arthritis (RA) [5] . This approach might not be adapted to all patients. Indeed, we report the occurrence of typical RA in a patient with the HIM syndrome, suggesting that the CD40 pathway does not play a critical role in the pathogenesis of at least some patients with RA.
INTERACTIONS between the CD40 antigen, a receptor expressed on B cells, and its ligand, a 39 kDa protein expressed on the surface of activated T cells, are involved in B-cell activation and isotype switching and are essential in the development of thymus-dependent immunity [1] . This has been fairly well documented by the recent recognition that immunodeficiency with normal or elevated levels of IgM [so-called hyper-IgM (HIM) syndrome] may result from defects in the expression of CD40 ligand (CD40L) by activated T cells or defects in CD40-mediated signal transduction in B cells [2, 3] .
Interference with CD40L-CD40 interactions has been advocated as a potential immunosuppressive strategy that can be applied to the treatment of immune diseases [4] . Because the administration of an antibody to CD40L inhibits the onset of collagen type II-induced arthritis in susceptible strains of mice, blockade of the CD40 pathway has been proposed in the treatment of human rheumatoid arthritis (RA) [5] . This approach might not be adapted to all patients. Indeed, we report the occurrence of typical RA in a patient with the HIM syndrome, suggesting that the CD40 pathway does not play a critical role in the pathogenesis of at least some patients with RA.
PATIENT AND METHODS

Case report
The patient, a Caucasian male without any unusual familial history, had had recurrent bronchopulmonary and Later on, the patient was lost to follow-up during 3 yr while he was receiving only low doses of oral corticosteroids. At age 52, chest examinations, including a CT scan, disclosed bilateral bronchiectasis and radiographs of sinus revealed maxillary sinusitis. Biological data were unchanged; in particular, serum Ig levels were similar and tests for RF were still negative. The patient's HLA class I antigens were A1/24; B14/57; HLA class II genotypes, as determined using restriction fragment length polymorphism and polymerase chain reaction (PCR) analysis, were DRB 1*0102,07, DQB 1*0501,0201 and DPB 1*0401,0401.
Infusions of i.v. Ig were administered every 3 weeks and steroid therapy (oral prednisone 7 mg/day) was continued. The polyarthritis slowly worsened with progressive joint deformations and destructions, particularly of IPP, MCP and the wrists of both hands ( Fig. 1) and of the right knee, which ultimately required surgical replacement. Cultures of synovial tissue were negative, including those performed on media specific for mycoplasmas (Shepard and Hayslick media). DNA extracted from synovial tissue samples was studied using PCR-based methods performed with Mycoplasmaspecific primers [6] ; whereas HLA controls were positive, no nucleic acid sequences of Mycoplasma fermentans, M. hominis, M. genitalium, hi. pneumoniae and Ureaplasma urealyticum were detected (data not shown).
Immunological studies were performed before the surgical procedure, whereas the patient was still treated with intermittent i.v. Ig therapy and low doses of prednisone.
Immunological studies
In vitro studies were performed as previously described [7] . Briefly, purified T-and B-cell preparations were obtained from blood mononuclear cells by resetting and monocyte depletion. T cells were activated by incubation in phorbol myristate acetate (PMA) and ionomycin. CD40 ligand expression was tested by immunofluorescence using a CD40 Fc-y fusion protein and a fluorescein-labelled anti-mouse Fc-y fragment antiserum.
For B-cell activation, purified B cells of the patient and of a normal donor were cultured in the presence of anti-CD40 monoclonal antibody (Mab) 89 and irradiated CDW 32 FcyRII-transfected L cells. Recombinant interleukin 4 (rIL4) or interleukin 10 (rILlO) was added at 10 ng/ml, and IgM, IgG and IgA levels in supematants were determined using ELISA methods as previously described [7] .
RESULTS AND DISCUSSION
The immunodeficiency of our patient features most clinical and biological characteristics of the HIM syndrome, namely recurrent bacterial infections, and very low or absent IgG, IgA and IgE contrasting with elevated levels of IgM [8] . The physiopathogenesis of this rare syndrome has recently been elucidated. It involves T-B-cell collaboration via interactions between CD40 ligand (gp39 or CD40L) on activated T cells and CD40 on B cells [1, 2] . This pathway is of critical importance for B-cell activation, proliferation, protection from apoptosis and, in the presence of cytokines, isotype switching [1] . HIM syndrome usually occurs as a familial disorder, with either X-linked or autosomal modes of inheritance; rare secondary forms, most frequently associated with congenital rubella, have been described [8] . In most patients with the X-linked form, T cells fail to bind CD40 molecules, because of mutations or deletions in the CD40L gene. In other patients, in vitro activated T cells can express normal or reduced amounts of functional CD40L molecules and HIM syndrome results from intrinsic defects in CD40-mediated signal transduction in B cells [2, 3, 9] . Based on this distinction, patients with HIM can be classified into those who are CD40L-and CD40L+ [2] .
In our patient, CD40L was normally expressed on PMA-and ionomycin-activated T cells, and CD40 molecules were detected on B cells (data not shown). B lymphocytes, when cultured in vitro, spontaneously produced large amounts of IgM, but were unable to switch and produce IgG or IgA in the presence of anti-CD40 Mab and of rIL4 or rILlO (Table I) . Accordingly, the patient probably had the CD40L+ type of HIM syndrome. The absence of a familial history suggested an autosomal mode of inheritance, but an X-linked form could not formally be ruled out since a third to a half of the patients with X-linked HIM syndrome are considered sporadic cases.
In addition to HIM syndrome, our patient had a chronic destructive, bilateral and symmetrical polyarthritis which was associated with typical rheumatoid nodules and mainly involved the knees, elbows, IPP, MCP and wrists, including destructive bilateral carpal lesions (Fig. 1) . Infectious or aseptic arthritis can occur in association with hypogammaglobulinaemic states, including the HIM syndrome [8, 10, 11] . Polyarticular and erosive septic arthritis, sometimes with s.c. nodules, have been described, due to mycoplasmas [10, 12] . In our patient, this bacterial agent was ruled out since a specific PCR performed on synovial tissue samples was negative. Aseptic hypogammaglobulinaemia-associated polyarthritis of unknown cause has also been described, but very few cases were destructive and they might represent true RA [10, 11] . Our patient's rheumatic disease fulfilled the American College of Rheumatology criteria for the diagnosis of RA. Moreover, he expressed HLA-DR1, which is often associated with RA, particularly when bearing subtypes DRBl*0101 or DRBl*0102 [13] .
The absence of RF in our patient's serum may appear unexpected since he had a nodular RA and a polyclonal HIM. It is, however, in keeping with current concepts on the generation of RF in RA, which emphasize the importance of T-cell-dependent antigendriven mechanisms leading to the selection of high-affinity RF-producing B cells featured by frequent immunoglobulin gene somatic mutations [14] . Such a process is unlikely in patients with HIM who, lacking a functional CD40 pathway, fail to produce secondary antibody responses and high-affinity IgM directed towards most T-dependent antigens [8] . On the other hand, the development of erosive arthritis in our patient confirms that, in addition to mechanisms involving a normal cooperation between T and B cells, other mechanisms, B or T cell independent, may participate in the aetiopathogenesis of RA [15] .
In a murine model of collagen-induced arthritis, the administration of antibodies blocking the binding of CD40L to CD40 has been shown to prevent the development of joint inflammation, the infiltration of inflammatory cells into the subsynovial tissue, and the erosion of cartilage and bone [4] . Our report shows that RA can develop in at least some patients with dysfunction of the CD40 pathway. Accordingly, results from the animal model must be critically extended to the human disease and blockade of the CD40 pathway, which has been proposed as a potential therapeutic measure in the control of human RA [4] , might not be adapted to all patients.
